Drug Trial Radar · NCT05208047
(Peak) A Phase 3 Randomized Trial of Bezuclastinib (CGT9486)+Sunitinib vs. Sunitinib in Participants With Gastrointestinal Stromal Tumors
Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
482
Planned (sponsor's estimate)
Start
Apr 14, 2022
Primary completion
Sep 30, 2025
Study completion Jan 2030
Sponsor
- Lead sponsor
- Cogent Biosciences, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jan 26, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 3, open-label, international, multicenter study of bezuclastinib in combination with sunitinib. This is a multi-part study that will enroll approximately 482 participants. Part 1 consists of two evaluations: 1) confirming the dose of an updated formulation of bezuclastinib to be used in subsequent parts in approximately 20 participants who have received at least one prior line of therapy for Gastrointestinal Stromal Tumors (GIST) and 2) evaluating the potential for drug-drug interactions between bezuclastinib and sunitinib in approximately 18 participants who have received at least two prior tyrosine kinase inhibitors (TKIs) for GISTs. The second part of the study will enroll approximately 388 participants who are intolerant to, or who failed prior treatment with imatinib only and will compare the efficacy of bezuclastinib plus sunitinib to sunitinib alone with participants being randomized in a 1:1 manner. This study also contains two substudies: 1) a drug-drug interactions (DDI) substudy will investigate the potential for bezuclastinib to be a Cytochrome P450 (CYP)3A4 inducer in approximately 16 participants who have received at least one prior line of therapy for GIST and 2) a substudy intended to test the efficacy of bezuclastinib and sunitinib as first-line (1L) treatment of GIST in approximately 40 participants with KIT exon 9 mutations and no prior systemic therapy (with the exception of up to 10 participants with ongoing imatinib therapy of ≤4 weeks).
Conditions
- Advanced Gastrointestinal Stromal Tumors
- Metastatic Cancer
Interventions
BezuclastinibDrug
Participants will receive bezuclastinib orally until study stopping rules are met.
BezuclastinibDrug
Participants will receive bezuclastinib until steady state then both bezuclastinib and sunitinib orally until study stopping rules are met.
SunitinibDrug
Participants will receive sunitinib until steady state then both sunitinib and bezuclastinib orally until study stopping rules are met.
SunitinibDrug
Participants will receive sunitinib orally until study stopping rules are met.
MidazolamDrug
Participants will receive a single-dose of midazolam on Day 1 and Day 15
BezuclastinibDrug
Participants will receive bezuclastinib orally starting on Day 2 until study stopping rules are met.
SunitinibDrug
Participants will receive bezuclastinib until steady state then both sunitinib and bezuclastinib orally until study stopping rules are met.
BezuclastinibDrug
Participants will receive sunitinib until steady state then both bezuclastinib and sunitinib orally until study stopping rules are met.
SunitinibDrug
Participants will receive sunitinib orally starting on Day 16 until study stopping rules are met.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1a - pharmacokinetics - CmaxTime frame: 16 days
- Part 1a - pharmacokinetics - AUCTime frame: 16 days
- Part 1b - pharmacokinetics - CmaxTime frame: 14 days
- Part 1b - pharmacokinetics - AUCTime frame: 14 days
- Part 1b - pharmacokinetics - TmaxTime frame: 14 days
- Part 2 - Progression Free Survival (PFS)Time frame: Approximately 48 months
- DDI Substudy - pharmacokinetics - AUCTime frame: 16 days
- DDI Substudy - pharmacokinetics - CmaxTime frame: 14 days
Locations
126 sites in 22 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama · Withdrawn
Mayo Clinic
Scottsdale, Arizona · Recruiting
University of Arizona- Cancer Center
Tucson, Arizona · Active not recruiting
City of Hope
Duarte, California · Recruiting
University of California, Los Angeles (UCLA)
Los Angeles, California · Active not recruiting
University of California, San Diego (UCSD)
San Diego, California · Recruiting
University of California, San Francisco
San Francisco, California · Active not recruiting
University of Colorado Denver
Denver, Colorado · Recruiting
MedStar Washington Hospital Center
Washington D.C., District of Columbia · Recruiting
Mayo Clinic Jacksonville
Jacksonville, Florida · Recruiting
University of Miami - Sylvester Comprehensive Cancer Center
Miami, Florida · Recruiting
Mid Florida Hematology and Oncology Center
Orange City, Florida · Withdrawn
Orlando Health Cancer Institute
Orlando, Florida · Recruiting
Moffitt Cancer Center
Tampa, Florida · Recruiting
Northwestern University
Chicago, Illinois · Recruiting
University of Iowa Hospital and Clinics
Iowa City, Iowa · Recruiting
University of Kansas Cancer Center
Kansas City, Kansas · Active not recruiting
Dana-Farber Cancer Institute
Boston, Massachusetts · Recruiting
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan · Recruiting
Mayo Clinic
Rochester, Minnesota · Recruiting
Washington University
St Louis, Missouri · Recruiting
Nebraska Methodist Hospital
Omaha, Nebraska · Recruiting
Roswell Park Comprehensive Cancer Center
Buffalo, New York · Active not recruiting
Memorial Sloan Kettering Cancer Center
New York, New York · Recruiting
Duke University
Durham, North Carolina · Recruiting
The Cleveland Clinic Foundation
Cleveland, Ohio · Recruiting
The Ohio State University Comprehensive Cancer Center
Columbus, Ohio · Recruiting
University of Toledo Medical Center
Toledo, Ohio · Withdrawn
Oregon Health & Science University (OHSU)
Portland, Oregon · Recruiting
Fox Chase Cancer Center
Philadelphia, Pennsylvania · Recruiting
University of Pittsburgh Medical Center - Hillman Cancer Center
Pittsburgh, Pennsylvania · Recruiting
University of Tennessee
Knoxville, Tennessee · Withdrawn
Vanderbilt University Medical Center
Nashville, Tennessee · Recruiting
The University of Texas MD Anderson Cancer Center
Houston, Texas · Recruiting
Fred Hutchinson Cancer Center
Seattle, Washington · Active not recruiting
University of Wisconsin - Carbone Cancer Center
Madison, Wisconsin · Recruiting
Instituto Alexander Fleming
Buenos Aires, Argentina · Active not recruiting
Instituto Oncologico de Cordoba (IONC)
Córdoba, Argentina · Active not recruiting
Bankstown-Lidcombe Hospital
Bankstown, Australia · Active not recruiting
Sir Charles Gairdner Hospital
Nedlands, Western Australia, Australia · Active not recruiting
Showing 40 of 126 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.